Healthcare technology can now predict, with real accuracy, which patients are at high risk for hospital readmission, chronic disease progression, or a health crisis before it happens. The uncomfortable trend underneath that capability in 2026: knowing this doesn’t always translate into providers actually being paid to act on it. This is the central tension shaping value-based care right now, and it’s worth understanding clearly. 

The Core Problem: Only 30–40% of Healthcare Operates Under Value-Based Contracts 

Despite years of industry conversation about the shift from fee-for-service to value-based care, only 30–40% of U.S. healthcare currently operates under value-based contracts. That’s the number that explains almost everything else happening in this space in 2026. 

This creates what’s increasingly being described as a structural paradox: AI can identify high-risk patients who need preventive care, but if that preventive care isn’t reimbursable under the payment model a provider operates within, there’s limited financial incentive to act on the AI’s insight — even when the clinical case for acting is clear. 

Why This Paradox Matters More in 2026 Than Previous Years 

This gap wasn’t as consequential when predictive tools were less accurate or less widely deployed. In 2026, that’s changed. AI-driven predictive analytics have matured to the point where they’re genuinely identifying actionable risk — but the payment infrastructure around them hasn’t kept pace. The result is a widening mismatch between what’s clinically possible and what’s financially incentivized. 

There’s a specific example that illustrates this clearly: if AI is automatically interacting with a patient, providing a diagnosis, or monitoring symptoms in the background, the clinician overseeing that process often doesn’t have a clear billing pathway for that time and oversight — meaning valuable clinical work is happening without a corresponding payment mechanism. 

What’s Expected to Change: CMS Experimentation With AI-Specific Payment Models 

In 2026, CMS (Centers for Medicare & Medicaid Services) is expected to launch experiments with new CPT codes and payment models designed explicitly for AI-first care. This is a meaningful signal — CMS has historically been cautious about creating new payment codes, and doing so specifically for AI-driven care indicates recognition that the reimbursement gap has become a genuine barrier to adoption, not just an administrative inconvenience. 

Why this ripples beyond Medicare: CMS coverage spans over 140 million Americans through Medicare, Medicaid, and CHIP. When CMS creates new payment codes or models, commercial insurers typically follow within 12–24 months. This means changes CMS makes in 2026 will likely shape commercial payer policy well into 2027 and 2028 — worth planning around now rather than waiting for the full rollout. 

What This Means for Healthcare Organizations Right Now 

1. Don’t assume clinical value automatically translates to financial sustainability. A predictive tool that correctly identifies high-risk patients is only operationally valuable if there’s a viable path to being reimbursed for the resulting intervention. Evaluate new AI or care-coordination investments with this reimbursement question built in from the start, not as an afterthought. 

2. Build the business case for AI-driven care explicitly, not just the clinical case. Industry voices are increasingly direct about this: it’s imperative to develop strong business models that make AI-driven clinical work profitable, not just clinically sound. This is what will ultimately offset rising medical costs system-wide, rather than adding a promising but financially unsustainable layer on top of existing operations. 

3. Watch CMS’s 2026 CPT code experiments closely. Organizations that adapt early to new AI-specific payment codes will be better positioned than those waiting for the eventual commercial payer follow-through 12–24 months later. 

Consumers Aren’t Waiting for the System to Catch Up 

While CMS experiments with payment codes and payers debate reimbursement frameworks, a parallel trend is accelerating: consumers are increasingly paying out of pocket for health services and tools, effectively forcing the system to respond to demand rather than waiting for formal reimbursement pathways to be established. Consumer health has experienced a genuine renaissance over the past few years, driven partly by this willingness to bypass traditional insurance-gated access when the value proposition is clear enough. 

This matters strategically: organizations building AI-driven or value-based care models may find a viable near-term path through direct-to-consumer offerings, even while the insurance-based reimbursement infrastructure is still catching up. 

The Underlying Shift: From Volume to Insight-Powered Engagement 

Beyond the reimbursement mechanics, there’s a broader strategic shift happening in how leading healthcare organizations think about value-based care. The differentiator going forward isn’t just adopting value-based contracts — it’s using behavioral insights and predictive analytics to anticipate patient needs, personalize outreach, and simplify access proactively. This lays the groundwork for AI-driven care to become financially sustainable as payment models catch up, rather than treating value-based transformation as a switch that flips once contracts change. 

A Practical Framework for Navigating This in 2026 

• Audit your current payer mix to understand what percentage of your patient population is genuinely under value-based versus fee-for-service arrangements 

• Map your AI and predictive tool investments against actual reimbursement pathways — not just clinical value — before scaling them further 

• Track CMS’s 2026 CPT code experiments specifically, since they’ll shape commercial payer policy on a 12–24 month lag 

• Consider direct-to-consumer offerings for AI-driven or preventive care services where insurance reimbursement remains structurally limited 

The Bottom Line 

Value-based care in 2026 is constrained less by clinical capability — AI-driven predictive analytics genuinely work — and more by a reimbursement infrastructure that hasn’t fully caught up to what’s now clinically possible. CMS’s expected 2026 experiments with AI-specific payment codes are the development to watch most closely, since they’ll set the direction commercial payers follow over the next two years. Until then, organizations that build the financial case alongside the clinical case — and consider direct-to-consumer paths where reimbursement lags — are best positioned to make value-based, AI-driven care actually sustainable. 

Frequently Asked Questions 

What percentage of U.S. healthcare currently operates under value-based care? Only 30–40% of U.S. healthcare currently operates under value-based contracts, which creates a persistent gap between clinically identified needs and what’s financially incentivized under current payment models. 

Why can AI identify healthcare needs that don’t get addressed? Because AI-driven insights, like flagging a high-risk patient needing preventive care, don’t automatically come with a reimbursement pathway — if the resulting care isn’t billable under a provider’s payment model, there’s limited financial incentive to act on it. 

Is CMS creating new payment codes for AI-driven healthcare? Yes — CMS is expected to launch experiments with new CPT codes and payment models designed explicitly for AI-first care in 2026, which will likely influence commercial payer policy within 12–24 months. 

How long does it typically take commercial insurers to follow CMS payment changes? Commercial insurers typically follow CMS’s lead on new payment codes and models within 12–24 months, given CMS’s scale covering over 140 million Americans through Medicare, Medicaid, and CHIP. 

Are patients paying out of pocket for AI-driven healthcare instead of waiting for insurance coverage? Yes — this is a growing trend, with consumer health experiencing significant growth as patients increasingly pay directly for services and tools rather than waiting for formal reimbursement frameworks to catch up. 

Building a business case for AI-driven or value-based care initiatives? Map your reimbursement pathways alongside the clinical evidence before scaling — the financial sustainability question is as critical as the clinical one in 2026.